We are monitoring the impact of COVID-19 on Europe Chlamydia Infection Diagnostics And Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 4961
Share on
Share on

Europe Chlamydia Infection Diagnostics and Therapeutics Market Research Report – Segmented By Product Type, End User and Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) – Industry Size, Share, Trends and Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 4961
Pages: 145

The size of the Europe Chlamydia Infection Diagnostics and Therapeutics market was around USD 0.59 billion in 2021. It is expected to grow at a CAGR of 5.9% to reach USD 0.79 billion by 2026. It captures 25% of the global market.

The chlamydia infection diagnostics and therapeutics market have a lot of promise, especially in developing regions such as Europe, due to the growing patient pool and vast unexplored opportunities.

The European market is likely to rise steadily in the foreseeable future, owing to an increased focus on treating sexually transmitted infections across Europe. In addition, improved diagnostic approaches for pelvic inflammatory illness and chlamydial infection symptoms are required in women at high risk of tubal damage. As a result, the number of chlamydia infection diagnoses continues to rise, and key factors such as a large pool of potential patients, government initiatives aimed at improving health care access, improving infrastructure, and increasing healthcare spending are expected to drive the market in Europe.

The number of sexually transmitted illnesses and chlamydia cases rises in Europe, the market for chlamydia infection diagnostics and therapeutics is growing. Furthermore, increasing government initiatives to raise public awareness about STDs and enhance public knowledge about STDs are propelling the market ahead. In particular, in response to the growing economic burden of STDs, government efforts to raise STD awareness have increased. The growth of the chlamydia infection treatment market is fueled by increased government-sponsored efforts to disseminate awareness and measures such as free diagnostic camps to promote regular health check-ups. As a result, the demand for frequent health examinations has risen, as has public awareness of the importance of disease screening.

However, despite the importance of frequent STD testing, many people avoid it owing to social shame; this can lead to poorer screening, prevention, and care, stifling the growth of the chlamydia infection treatment market in the European region. In addition, patients routinely withhold details about their sexual lives from doctors, reducing the market for chlamydia infection therapy. The market's expansion is likely to be constrained by a lack of laboratory experience and knowledge, as well as a lack of healthcare infrastructure. In countries, awareness of chlamydia infection diagnostic tests is extremely low.

This research report on the European chlamydia infection diagnostics and therapeutics market has been segmented & sub-segmented into the following categories:

By Product: 

  • Diagnostics
    • Nucleic Acid Amplification Tests (NAATs)
    • Direct Fluorescent Tests
    • PCR
  • Therapeutics
    • Macrolides
    • Quinolones
    • Sulfonamides
    • Tetracycline
    • Aminopenicillins

By End User: 

  • Diagnostics
    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
  • Therapeutics
    • Hospital Pharmacies
    • Drugstores
    • Retail Pharmacies
    • Online Pharmacies

By Country: 

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, Europe was the second-largest market in 2020. The UK was the market leader in Europe. The region's success has contributed to a well-established healthcare market, rising chlamydia infection rates, and the availability of well-defined reimbursement policies from state and private health insurance firms.

In Europe, countries such as Germany and the United Kingdom are flourishing due to their enormous ability to quickly adopt breakthrough treatments and the presence of several strengthening economies.

KEY MARKET PLAYERS:

Bio-Rad Laboratories, Novartis AG, F Hoffmann-La Roche, Abbott Laboratories, Danaher. Other players in the market include bioMerieux, DiaSorin SpA, Siemens AG, Thermo Fisher Scientific, and Becton Dickinson and Company, a few of the prominent companies in the European market.

1. Introduction                                

               1.1 Market Definition                    

               1.2 Study Deliverables                  

               1.3 Base Currency, Base Year and Forecast Periods                          

               1.4 General Study Assumptions                 

2. Research Methodology                                          

               2.1 Introduction                             

               2.2 Research Phases                      

                              2.2.1 Secondary Research           

                              2.2.2 Primary Research 

                              2.2.3 Econometric Modelling      

                              2.2.4 Expert Validation  

               2.3 Analysis Design                        

               2.4 Study Timeline                         

3. Overview                                     

               3.1 Executive Summary                

               3.2 Key Inferences                         

               3.3 Epidemology                            

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

               4.1 Market Drivers                         

               4.2 Market Restraints                   

               4.3 Key Challenges                         

               4.4 Current Opportunities in the Market               

5. Market Segmentation                                            

               5.1 Product Type                            

                              5.1.1 Introduction           

                              5.1.2 Diagnostics             

                                             5.1.2.1 Nucleic Acid Amplification Tests (NAATs)

                                             5.1.2.2 Direct Fluorescent Tests

                                             5.1.2.3 PCR

                              5.1.3 Therapeutics          

                                             5.1.3.1 Macrolides

                                             5.1.3.2 Quinolones

                                             5.1.3.3 Sulfonamides

                                             5.1.3.4 Tetracycline

                                             5.1.3.5 Aminopenicillins

                              5.1.4 Y-o-Y Growth Analysis, By Product Type     

                              5.1.5 Market Attractiveness Analysis, By Product Type    

                              5.1.6 Market Share Analysis, By Product Type     

               5.2 End User                     

                              5.2.1 Introduction           

                              5.2.2 Diagnostics             

                                             5.2.2.1 Hospitals

                                             5.2.2.2 Specialty Clinics

                                             5.2.2.3 Diagnostic Centers

                              5.2.3 Therapeutics          

                                             5.2.3.1 Hospital Pharmacies

                                             5.2.3.2 Drugstores

                                             5.2.3.3 Retail Pharmacies

                                             5.2.3.4 Online Pharmacies

                              5.2.4 Y-o-Y Growth Analysis, By End User             

                              5.2.5 Market Attractiveness Analysis, By End User            

                              5.2.6 Market Share Analysis, By End User             

6. Geographical Analysis                                            

               6.1 Introduction                             

                              6.1.1 Regional Trends    

                              6.1.2 Impact Analysis     

                              6.1.3 Y-o-Y Growth Analysis        

                                             6.1.3.1 By Geographical Area

                                             6.1.3.2 By Product Type

                                             6.1.3.3 By End User

                              6.1.4  Market Attractiveness Analysis      

                                             6.1.4.1 By Geographical Area

                                             6.1.4.2 By Product Type

                                             6.1.4.3 By End User

                              6.1.5  Market Share Analysis       

                                             6.1.5.1 By Geographical Area

                                             6.1.5.2 By Product Type

                                             6.1.5.3 By End User

               6.2 U.K                

               6.3 Spain                           

               6.4 Germany                     

               6.5 Italy                             

               6.6 France                         

7. Strategic Analysis                                      

               7.1 PESTLE analysis                        

                              7.1.1 Political    

                              7.1.2 Economic 

                              7.1.3 Social        

                              7.1.4 Technological        

                              7.1.5 Legal         

                              7.1.6 Environmental       

               7.2 Porter’s Five analysis                             

                              7.2.1 Bargaining Power of Suppliers         

                              7.2.2 Bargaining Power of Consumers     

                              7.2.3 Threat of New Entrants      

                              7.2.4 Threat of Substitute Products and Services

                              7.2.5 Competitive Rivalry within the Industry      

8. Market Leaders' Analysis                                       

               8.1 Bio Rad laboratories               

                              8.1.1 Overview 

                              8.1.2 Product Analysis   

                              8.1.3 Financial analysis  

                              8.1.4 Recent Developments        

                              8.1.5 SWOT analysis       

                              8.1.6 Analyst View          

               8.2 Novartis AG               

               8.3 F Hoffmann-La Roche                           

               8.4 Abbott Laboratories               

               8.5 Danaher                      

               8.6 bioMerieux                

               8.7 DiaSorin SpA                             

               8.8 Siemens AG               

               8.9 Thermo Fisher Scientific                       

               8.10 Becton Dickinson and Company                     

9. Competitive Landscape                                         

               9.1 Market share analysis                           

               9.2 Merger and Acquisition Analysis                       

               9.3 Agreements, collaborations and Joint Ventures                          

               9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                          

               a) List of Tables                

               b) List of Figures                             

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms product type and Packaged Containers along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2021 to 2026 (USD Billion)
  2. Europe Diagnostics Market, By Region, From 2021 to 2026 (USD Billion)
  3. Europe Therapeutics Market, By Region, From 2021 to 2026 (USD Billion)
  4. Europe Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2021 to 2026 (USD Billion)
  5. Europe Diagnostics Market, By Region, From 2021 to 2026 (USD Billion)
  6. Europe Therapeutics Market, By Region, From 2021 to 2026 (USD Billion)
  7. U.K. Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2021 to 2026 (USD Billion)
  8. U.K. Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2021 to 2026 (USD Billion)
  9. Germany Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2021 to 2026 (USD Billion)
  10. Germany Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2021 to 2026 (USD Billion)
  11. France Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2021 to 2026 (USD Billion)
  12. France Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2021 to 2026 (USD Billion)
  13. Italy Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2021 to 2026 (USD Billion)
  14. Italy Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2021 to 2026 (USD Billion)
  15. Spain Chlamydia Infection Diagnostics and Therapeutics Market, By Product Type, From 2021 to 2026 (USD Billion)
  16. Spain Chlamydia Infection Diagnostics and Therapeutics Market, By End User, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample